Establishment and characterization of a new cell line, FRTK-1, derived from human malignant rhabdoid tumor of the kidney, with overexpression of epidermal growth factor receptor and cyclooxygenase-2

Oncology Reports

Volumn 16, Issue 2, 2006, Pages 265-271

  Hakozaki, Michiyuki ^a   Hojo, Hiroshi ^a   Sato, Michiko ^a   Kaneko, Yasuhiko ^b   Watanabe, Naoki ^b,c   Kikuchi, Shinichi ^a   Abe, Masafumi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

Author keywords

Cyclooxygenase 2; Epidermal growth factor receptor; FRTK 1 cell line; hSNF5 INI1 gene; Malignant rhabdoid tumor of the kidney

Indexed keywords

CYCLOOXYGENASE 2; DNA BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; NONHISTONE PROTEIN; SMARCB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADOLESCENT; ARTICLE; CELL ADHESION; CHROMOSOME ANALYSIS; DNA SEQUENCE; ENZYMOLOGY; GENETICS; HUMAN; KIDNEY TUMOR; MALE; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOID TUMOR; STOP CODON; TUMOR CELL LINE; WESTERN BLOTTING;

ADOLESCENT; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; CODON, NONSENSE; CYCLOOXYGENASE 2; CYTOGENETIC ANALYSIS; DNA-BINDING PROTEINS; HUMANS; KIDNEY NEOPLASMS; MALE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOID TUMOR; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS;

EID: 33748557472     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.2.265     Document Type: Article

References (41)

1. Beckwith JB and Palmer NF: Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer 41: 1937-1948, 1978. (Pubitemid 8335406)
2. Weeks DA, Beckwith JB, Mierau GW and Luckey DW: Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms' Tumor Study Pathology Center. Am J Surg Pathol 13: 439-458, 1989. (Pubitemid 19149607)
3. Gansler T, Gerald W, Anderson G, Gramling TS, Williams CH, Sens D and Garvin AJ: Characterization of a cell line derived from rhabdoid tumor of kidney. Hum Pathol 22: 259-266, 1991.
4. Ota S, Crabbe DC, Tran TN, Triche TJ and Shimada H: Malignant rhabdoid tumor. A study with two established cell lines. Cancer 71: 2862-2872, 1993. (Pubitemid 23120069)
5. Hirose M, Yamada T, Abe T, Hirose T, Shimizu E, Yamamoto Y, Kagami S, Takano S, Yamaguchi T and Kuroda Y: Establishment and characterization of two cultured cell lines derived from malignant rhabdoid tumors of the kidney. Int J Cancer 67: 218-223, 1996. (Pubitemid 26274153)
6. Rosson GB, Hazen-Martin DJ, Biegel JA, Willingham MC, Garvin AJ, Oswald BW, Wainwright L, Brownlee NA and Wright CF: Establishment and molecular characterization of five cell lines derived from renal and extrarenal malignant rhabdoid tumors. Mod Pathol 11: 1228-1237, 1998. (Pubitemid 29009334)
7. Sugimoto T, Hosoi H, Horii Y, Ishida H, Mine H, Takahashi K, Abe T, Ohta S and Sawada T: Malignant rhabdoid-tumor cell line showing neural and smooth-muscle-cell phenotypes. Int J Cancer 82: 678-686, 1999. (Pubitemid 29356966)
8. Kinoshita Y, Tamiya S, Oda Y, Mimori K, Inoue H, Ohta S, Tajiri T, Suita S and Tsuneyoshi M: Establishment and characterization of malignant rhabdoid tumor of the kidney. Oncol Rep 8: 43-48, 2001.
9. Handgretinger R, Kimmig A, Koscielnak E, Schmidt D, Rudolph G, Wolburg H, Paulus W, Schilbach-Stueckle K, Ottenlinger C, Menrad A, Sproll M, Bruchelt G, Dopfer R and Treuner J: Establishment and characterization of a cell line (Wa-2) derived from an extrarenal rhabdoid tumor. Cancer Res 50: 2177-2182, 1990. (Pubitemid 20115096)
10. Karnes PS, Tran TN, Cui MY, Bogenmann E, Shimada H and Ying KL: Establishment of a rhabdoid tumor cell line with a specific chromosomal abnormality, 46, XY). Cancer Genet Cytogenet 56: 31-38, 1991.
11. Misawa A, Hosoi H, Imoto I, Iehara T, Sugimoto T and Inazawa J: Translocation (1;22) (p36;q11.2) with concurrent del(22) (q11.2) resulted in homozygous deletion of SNF5/INI1 in a newly established cell line derived from extrarenal rhabdoid tumor. J Hum Genet 49: 586-589, 2004. (Pubitemid 39506543)
12. Kuroda H, Moritake H, Sawada K, Kuwahara Y, Imoto I, Inazawa J and Sugimoto T: Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16. Cancer Genet Cytogenet 158: 172-179, 2005. (Pubitemid 40417700)
13. Yachnis AT, Neubauer D and Muir D: Characterization of a primary central nervous system atypical teratoid/rhabdoid tumor and derivative cell line: immunophenotype and neoplastic properties. J Neuropathol Exp Neurol 57: 961-971, 1998. (Pubitemid 28478006)
14. Murakami Y, Hayashi K and Sekiya T: Detection of aberrations the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res 51: 3356-3361, 1991.
15. Kuze T, Nakamura N, Hashimoto Y, Hojo H, Abe M and Wakasa H: The relationship between the gene mutation of p53 and the protein expression of p53 and Ki-67 in non-Hodgkin's lymphomas. Pathol Int 46: 130-136, 1996. (Pubitemid 26171710)
16. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A and Delattre O: Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394: 203-206, 1998. (Pubitemid 28325977)
17. Abe M, Nakamura N, Fukuhara S, Hayashi T, Kawakami K, Kita K, Kinoshita T, Ohsato T and Wakasa H: A newly established human acute lymphoblastic leukemia cell line with characteristics of the earliest B-cell maturation. Virchows Arch 59: 107-113, 1990. (Pubitemid 20240898)
18. Hashimoto Y, Nakamura N, Kuze T, Abe M and Wakasa H: Intranuclear expression of cyclin D1 protein as a useful prognostic marker for mantle cell lymphoma. Fukushima J Med Sci 43: 87-98, 1997.
19. Narita T, Taga T, Sugita K, Nakazawa S and Ohta S: The autocrine loop of epidermal growth factor receptor-epidermal growth factor/transforming growth factor-alpha in malignant rhabdoid tumor cell lines: heterogeneity of autocrine mechanism in TTC549. Jpn J Cancer Res 92: 269-278, 2001. (Pubitemid 32288288)
20. Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC and Yang PC: Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 115: 545-555, 2005. (Pubitemid 40656711)
21. Kalpana GV, Marmon S, Wang W, Crabtree GR and Goff SP: Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 266: 2002-2006, 1994.
22. Wang W, Cote J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M, Workman JL and Crabtree GR: Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J 15: 5370-5382, 1996. (Pubitemid 26336219)
23. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM and Fogelgren B: Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59: 74-79, 1999. (Pubitemid 29062960)
24. Uno K, Takita J, Yokomori K, Tanaka Y, Ohta S, Shimada H, Gilles FH, Sugita K, Abe S, Sako M, Hashizume K and Hayashi Y: Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors. Genes Chromosomes Cancer 34: 33-41, 2002. (Pubitemid 34260594)
25. Zhang ZK, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D and Kalpana GV: Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol 22: 5975-5988, 2002. (Pubitemid 34815844)
26. Klochendler-Yeivin A, Fiette L, Barra J, Muchardt C, Babinet C and Yaniv M: The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep 1: 500-506, 2000.
27. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD and Orkin SH: Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci USA 97: 13796-13800, 2000.
28. Guidi CJ, Sands AT, Zambrowicz BP, Turner TK, Demers DA, Webster W, Smith TW, Imbalzano AN and Jones SN: Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 21: 3598-3603, 2001. (Pubitemid 32381795)
29. Roberts CW, Leroux MM, Fleming MD and Orkin SH: Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2: 415-425, 2002. (Pubitemid 41039107)
30. Judkins AR, Mauger J, Ht A, Rorke LB and Biegel JA: Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 28: 644-650, 2004. (Pubitemid 38579568)
31. Hoot AC, Russo P, Judkins AR, Perlman EJ and Biegel JA: Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol 28: 1485-1491, 2004. (Pubitemid 39425515)
32. Kinoshita Y, Shiratsuchi H, Tamiya S, Oshiro Y, Hachitanda Y, Oda Y, Suita S and Tsuneyoshi M: Mutations of the p53 gene in malignant rhabdoid tumors of soft tissue and the kidney: immunohistochemical and DNA direct sequencing analysis. J Cancer Res Clin Oncol 127: 351-358, 2001. (Pubitemid 32453677)
33. Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37: S9-S15, 2001. (Pubitemid 32938124)
34. Holbro T, Civenni G and Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 284: 99-110, 2003. (Pubitemid 36331969)
35. Kuwahara Y, Hosoi H, Osone S, Kita M, Iehara T, Kuroda H and Sugimoto T: Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin Cancer Res 10: 5940-5948, 2004. (Pubitemid 39180976)
36. Vane JR, Bakhle YS and Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120, 1998. (Pubitemid 28231490)
37. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, van de Putte LB and Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998. (Pubitemid 28418937)
38. Gately S and Li WW: Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31: 2-11, 2004. (Pubitemid 38879409)
39. Dickens DS and Cripe TP: Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J Pediatr Hematol Oncol 25: 709-714, 2003. (Pubitemid 37087507)
40. Yamashita H, Osaki M, Honjo S, Yoshida H, Teshima R and Ito H: A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line. Anticancer Res 23: 4671-4676, 2003. (Pubitemid 38173883)
41. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K and DuBois RN: Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23: 254-266, 2005. (Pubitemid 46206877)